SAN FRANCISCO — Agios Pharmaceuticals intends to double the number of approved medicines it sells from two to four within the next six years, while also expanding into new indications and deepening its pipeline by another two programs.
The new Agios (AGIO) strategic plan — including a mandate to trim financial losses and become cash-flow positive — was announced Sunday ahead of a presentation by CEO Jackie Fouse on Monday morning at the J.P. Morgan Healthcare Conference.
“Agios has accomplished a lot in 10 years, so this is not a situation where things are broken and I need to fix them,” said Fouse, speaking to STAT from the company’s Cambridge, Mass., headquarters ahead of the J.P. Morgan meeting. “I want to allow the foundational science of this company and its commitment to patients continue to take us places, but we need to be more disciplined and focused.”
About the Author Reprints
